Braidwell LP Grows Position in Xencor, Inc. (NASDAQ:XNCR)

Braidwell LP grew its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 32.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 615,531 shares of the biopharmaceutical company’s stock after purchasing an additional 149,083 shares during the quarter. Braidwell LP’s holdings in Xencor were worth $14,145,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in XNCR. Barclays PLC lifted its position in shares of Xencor by 100.7% during the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company’s stock valued at $3,128,000 after purchasing an additional 78,066 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Xencor by 2.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 130,354 shares of the biopharmaceutical company’s stock valued at $2,621,000 after buying an additional 3,635 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Xencor by 31.0% during the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 508 shares in the last quarter. KBC Group NV boosted its stake in shares of Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 813 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Xencor by 24.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,839 shares of the biopharmaceutical company’s stock valued at $341,000 after acquiring an additional 2,946 shares in the last quarter.

Xencor Stock Down 4.8 %

XNCR stock opened at $10.72 on Tuesday. The stock has a fifty day moving average of $11.24 and a 200-day moving average of $17.97. Xencor, Inc. has a fifty-two week low of $7.16 and a fifty-two week high of $27.24. The company has a market capitalization of $762.75 million, a price-to-earnings ratio of -3.35 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23.

Xencor (NASDAQ:XNCR) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.19. The firm had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. As a group, equities research analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Wedbush reiterated an “outperform” rating and set a $31.00 price target on shares of Xencor in a report on Wednesday, April 30th. William Blair initiated coverage on Xencor in a research note on Monday, April 21st. They set an “outperform” rating on the stock. StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. Finally, Wells Fargo & Company decreased their price objective on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Xencor presently has a consensus rating of “Moderate Buy” and an average price target of $32.86.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.